June 2027 Options Now Available For Philip Morris International (PM)

Philip Morris International (PM) is being presented with two option-income strategies around the stock price of $172.18: a sell-to-open $170 put (bid $18.40) which nets an effective cost basis of $151.60 and is estimated to have a 58% chance of expiring worthless, producing a 10.82% return (7.64% annualized) on cash at risk; and a covered-call using the $175 strike (bid $18.00) that would produce a 12.09% total return if called at the June 2027 expiry and has a 46% chance of expiring worthless, yielding a 10.45% boost (7.38% annualized). Implied volatility is roughly 27–28% (trailing 12‑month volatility 27%), and Stock Options Channel will track contract odds and histories on its site for ongoing monitoring.

Analysis

Market structure: The option quotes imply immediate winners are option premium collectors (cash‑secured put sellers, covered‑call writers) and brokerages collecting commission/financing; implied odds (put expire worthless 58%, call 46%) and YieldBoosts of ~10.5–10.8% (7.4–7.6% annualized) make yield harvesting attractive if comfortable owning PM at $151.60 (put assignment). Supply/demand for downside protection is moderate given realized 12‑month vol ≈27% vs implied 27–28%, so options are fairly priced — not showing a stress premium. Cross-asset: a material negative regulatory shock would widen credit spreads in EM issuers and strengthen USD (flight to safety), amplifying FX headwinds for PM.

Risk assessment: Tail risks center on regulatory/legal shocks (menthol/novel nicotine bans, large excise hikes) that could produce >30% drawdowns; litigation or sudden FDA rulings within 30–180 days are primary catalysts. Short horizon (days–weeks) risk is theta/IV movement around company events; medium (months) risk is FX and excise tax changes; long term (years) structural declines in combustible volume matter more than near‑term option carry. Hidden dependency: heavy emerging‑market revenue and excise‑tax elasticity mean assignment converts option sellers into concentrated operational exposure and FX risk overnight.

Trade implications: Direct actionable plays: (1) sell cash‑secured Jun‑2027 PM $170 put to collect $18.40 if willing to own at $151.60 (target size 2–4% portfolio); (2) buy PM and sell Jun‑2027 $175 call for a capped ~12.1% return if called. Use collars if downside protection needed (buy $150 put funded by closer calls). Entry triggers: execute if IV ≤ realized (≤28%) and only after no adverse regulatory headlines in prior 10 trading days; exit/roll if PM drops >12% or IV spikes >35%.

Contrarian angles: Consensus overlooks FX and excise‑tax convexity — option sellers are implicitly long these risks; the income trade is underpriced if a 10–20% regulatory shock occurs. Historical parallels (menthol ban scares) show swift 15–30% re‑ratings, so size positions conservatively and cap assignment exposure to <5% portfolio. Monitor implied vol breakpoint at 35% and regulatory filings (FDA, EU tax proposals) over next 30–90 days as kill‑switches.

Key Decisions for Investors

• Sell cash‑secured PM Jun‑2027 $170 put at ~18.40 (effective buy basis $151.60) as a 2–4% portfolio allocation if willing to own PM at that basis; close or roll if PM trades below $150 or IV >35% within 60 days.
• Establish 1–2% portfolio covered‑call: buy PM at market (~$172) and sell Jun‑2027 $175 call to lock ~10.45% premium boost (cap upside at ~12.1%); unwind if PM > $190 or if regulatory headlines hit within 30 days.
• For existing PM longs >3% portfolio, buy a protective Jun‑2027 $150 put and fund by selling nearer OTM calls (collar) to limit downside to ~13–15% over the contract life; re‑evaluate at quarterly earnings or any FDA decision.
• Pair trade: go long PM and short MO (Altria) size ratio 0.8 PM:1 MO notional for 1–2% net portfolio exposure — play PM international pricing power vs MO US regulatory concentration; exit if relative move >10% or on major tax/regulatory announcements.
• Avoid large naked short‑call or uncovered put exposure; cap aggregate option assignment risk to <5% portfolio and monitor IV and regulatory news daily (set alerts for IV >35% or PM price move >12% intraday).